JP4751482B2 - Contact lens solution - Google Patents

Description

  The present invention relates to a liquid agent for contact lenses, and in particular, a drug component contained in a liquid medium is sufficiently exerted by inclusion of the drug component in pores of a compound such as cyclodextrin. The present invention relates to a liquid agent for contact lenses that can advantageously solve the problem that it cannot be performed.

  Conventionally, for ophthalmic compositions such as liquids for contact lenses, prevention of adsorption of drug components to contact lenses and containers, improvement of solubility, reduction of bitterness, relaxation of irritation, thickening and moisturizing of liquids For the purpose of improving the properties, cyclodextrins are often included. For example, in Japanese Patent No. 3297969 (Patent Document 1), an eye drop containing a preservative having a cationic group (eye drop for contact lens), cyclodextrins, ethylenediaminetetraacetic acid or a salt thereof, and boric acid And / or borax. And according to such an eye drop, since it mix | blends cyclodextrin and ethylenediaminetetraacetic acid or its salt together with the antiseptic | preservative (bactericide) which has a cationic group, Adhesion of the preservative to the contact lens is sufficiently effectively suppressed without impairing the preservative power, and the preservative power is further enhanced since boric acid and / or borax are used in combination with the preservative. It is said that.

  However, in such eye drops (eye drops for contact lenses) disclosed in Patent Document 1, cyclodextrin is contained together with a preservative having a cationic group, so that the contact lens of such preservatives is used. However, such an antiseptic agent is included in the pores of the cyclodextrin in the eye drop, so that the preservative inherent in such an antiseptic agent can be prevented. The problem is that power cannot be fully exerted. For this reason, in such eye drops, in addition to the preservative having a cationic group, the eye drops further contain ethylenediaminetetraacetic acid, boric acid and / or borax, thereby providing antiseptic power. However, ethylenediaminetetraacetic acid, boric acid, and borax are highly toxic to the human eye. When such eye drops are used, depending on their concentration, There was concern about the adverse effects on

  Moreover, in the eye drop containing such cyclodextrin, various components generally contained in the eye drop, for example, an antiallergic agent, as a drug component other than the above-mentioned preservative in the eye drop And chemical ingredients such as anti-inflammatory agents, vasoconstrictors, and refreshing agents, these chemical ingredients are also included in the cyclodextrin pores, similar to the preservatives described above. As a result, there is an inherent problem that even in such a drug component, the drug action of those drugs cannot be fully exerted.

  Thus, in the ophthalmic composition containing a compound having a cyclic or cylindrical molecular structure such as cyclodextrin and capable of including another compound (drug component) together with the drug component. The problem is that various drug components are included in the pores of the cyclic or cylindrical molecular structure of such a compound, so that the drug action inherent to these drug components cannot be fully exhibited. It was something that existed.

Japanese Patent No. 3297969

  Here, the present invention has been made in the background of such circumstances, and the problem to be solved thereof is to form a ring or cylinder such as cyclodextrin together with a drug component in a liquid medium. It is an object of the present invention to provide a contact lens solution capable of advantageously exerting the drug action of a drug component even if it is a contact lens solution containing a compound having a molecular structure.

  As a result of intensive investigations to solve such problems, the present inventors have a cyclic or cylindrical molecular structure together with a drug component and include other compounds (drug components). By adding a compound (compound B) having a chain molecular structure and capable of being included in the compound A to the liquid medium containing the compound (compound A) that can be contacted, It has been found that the problem can be advantageously solved.

  Therefore, the present invention has been completed on the basis of such knowledge, and in order to solve the above-described problems, the compound A contains a compound A having a cyclic or cylindrical molecular structure together with a drug component. The gist of the liquid agent for contact lenses is characterized in that the liquid medium further contains a compound B having a chain molecular structure and capable of being included in the compound A.

  According to one of the desirable embodiments of the contact lens solution according to the present invention, the inclusion compound formed by inclusion of the compound B with the compound A in the liquid medium is a pseudorotaxane. It has a structure or pseudopolyrotaxane structure.

  Here, according to one of the preferable embodiments of the contact lens solution according to the present invention, the compound A and the compound B are contained in a weight ratio of 1000: 1 to 1: 1000, According to another preferred embodiment, the compound A is contained at a concentration of 0.001 to 20.0 w / w%.

  According to another preferred embodiment of the contact lens solution according to the present invention, the compound B is a water-soluble polymer having a weight average molecular weight of 500 or more, more preferably polyethylene glycol.

  Furthermore, according to another desirable aspect of the liquid agent for contact lenses according to the present invention, the compound A having a cyclic or cylindrical molecular structure is a cyclodextrin.

According to still another preferred embodiment of the contact lens solution according to the present invention, the compound A is α-cyclodextrin, and the compound B contains macrogol 600, macrogol 1000, macrogol 1500, macrogol. 1540, at least one selected from macro goal 4000 and macro goal 6000 .

  Furthermore, according to one of the other desirable embodiments of the contact lens solution according to the present invention, the drug component is an antiallergic agent, an anti-inflammatory agent, a vasoconstrictor, a refreshing agent, an antiseptic / bactericidal agent, and a focus control. It is at least one selected from a function improving agent, an intraocular pressure-lowering agent, vitamins, an antibacterial agent (antibiotic) and a surfactant.

  In addition, the present invention includes a predetermined drug component, compound A having a cyclic or cylindrical molecular structure, and compound B having a chain molecular structure and capable of being included in the compound A. In a liquid preparation, the compound B is included in the compound A to form a pseudorotaxane structure or a pseudopolyrotaxane structure, thereby controlling the drug action of the drug component, This is the gist.

  In the present invention, the liquid medium contains Compound A having a cyclic or cylindrical molecular structure and Compound B having a chain molecular structure and capable of being included in the Compound A. Thus, the chain portion of the compound B enters the pores of the cyclic or cylindrical structure of the compound to form an inclusion compound exhibiting a pseudorotaxane structure or a pseudopolyrotaxane structure. A gist of the method is also characterized by reducing toxicity. In addition, the compound B is more preferably polyethylene glycol or polyoxyethylene polyoxypropylene glycol.

  Therefore, in such a contact lens solution according to the present invention, a chain molecule is further contained in a liquid medium containing a compound A having a cyclic or cylindrical molecular structure together with a predetermined drug component. Since the compound B having a structure and capable of being included in the compound A is contained, the compound B can be competitively or exchanged with the drug component in the pores of the compound A. So that the drug action of the drug component can be advantageously controlled, so that the drug effect of the drug component cannot be fully exerted, It can be effectively suppressed or prevented.

  Moreover, in such a contact lens solution according to the present invention, an advantageous effect realized by incorporating a compound A having a cyclic or cylindrical molecular structure together with a drug component in a liquid medium. For example, the effect of suppressing the adsorption of drug components to contact lenses and containers, the effect of improving the solubility of poorly soluble substances, the effect of reducing bitterness, the effect of reducing irritation, and the effect of suppressing the decrease in viscosity have the chain molecular structure. However, the presence of the compound B which can be included in the compound A is not lost at all, and those effects can also be enjoyed advantageously.

  By the way, the liquid agent for contact lenses according to the present invention further comprises a compound having a chain molecular structure in a liquid medium containing a compound A having a cyclic or cylindrical molecular structure together with a predetermined drug component. Compound B, which can be included in A, is contained, and as the drug component there are known various drug components that have been conventionally incorporated in contact lens solutions (here, Can be used, and is not limited in any way, but particularly those that can be included in the compound A are preferably used ( In addition, “inclusion” includes those in which the drug component or compound B penetrates compound A. The same shall apply hereinafter. Examples of such drug components include antiallergic agents, anti-inflammatory agents, vasoconstrictors, refreshing agents, antiseptics / bactericides, focus control function improving agents, intraocular pressure-lowering agents, vitamins, antibacterial agents ( Antibiotics) and surfactants can be exemplified.

  Specifically, among the drug components exemplified above, the antiallergic agent is a component used for the treatment of hay fever, allergic conjunctivitis, and the like, specifically, mast cells such as cromoglycic acid and tranilast. Stabilizers and antihistamines such as chlorpheniramine maleate, diphenhydramine hydrochloride, amlexanox, ibudilast, tranilast, pemirolast potassium, emedastine fumarate, olopatadine hydrochloride, ebastine, acitazanolast, levocabastine, cetirizine hydrochloride, etc. However, it is generally used at a concentration of about 0.00001 to 5 w / w%.

  In addition, among the above-described drug components, the anti-inflammatory agent is a component used for suppressing inflammation in the eye caused by stress or wearing of a contact lens, regardless of whether it is steroidal or non-steroidal, for example, Glycyrrhizic acid and salts thereof, ε-aminocaproic acid, allantoin, sodium azulene sulfonate, berberine chloride, berberine sulfate, zinc sulfate, zinc lactate, lysozyme, fluorometholone, etc., generally about 0.0001 to 10 w / w%, More preferably, it is used at a concentration of about 0.001 to 5 w / w%.

  Furthermore, the above-mentioned vasoconstrictor is a component that acts on the scleral blood vessels in the eyeball, eliminates redness of the eye and has the effect of restoring eye strain, and includes, for example, epinephrine, hydrochloric acid Examples include epinephrine, ephedrine hydrochloride, naphazoline hydrochloride, naphazoline nitrate, phenylephrine hydrochloride, tetrahydrozoline hydrochloride, and the like. In addition, the content of the liquid for contact lenses is preferably about 0.0001 to 1 w / w%, more preferably 0.0003 to 0.1 w / w%.

  Furthermore, among the above-mentioned drug components, the refreshing agent is one that is included for the purpose of giving a refreshing feeling to the eyes or eliminating the feeling of foreign objects and itching when wearing contact lenses, For example, fennel oil, d-camphor, dl-camphor, cool mint no. 71212, geraniol, peppermint water, peppermint oil, bergamot oil, rose oil, lavender oil, d-borneol, dl-borneol (runa), l-menthol, dl-menthol, eucalyptus oil, linalool, N-ethyl-p -Menthane-3-carboxamide (for example, WS-3; Takasago International Corporation) and the like. Generally, the refreshing agent is about 0.0001 to 1 w / w%, more preferably 0. It is contained at a concentration of 0.001 to 0.1 w / w%.

  In addition, examples of antiseptics and bactericides include sorbic acid, potassium sorbate, benzoic acid or salts thereof, ethyl paraoxybenzoate, butyl paraoxybenzoate, propyl paraoxybenzoate, methyl paraoxybenzoate, chlorobutanol, chloride Polyquaterniums such as benzalkonium, polyhexamethylene biguanide (PHMB; polyhexanide hydrochloride), alkyldiaminoethylglycine hydrochloride, cetylpyridinium chloride (CPC), chlorhexidine, alexidine, chlorpheniramine or salts thereof, allantoin, polydronium chloride, etc. Among these preservatives, in the present invention, sorbic acid, potassium sorbate, benzalkonium chloride, polyhexamethylene biguanide, alkyldiaminoethyl glycine hydrochloride Chloride Poridoroniumu is, adverse effects on standard contact lens from where very small, in particular, is preferably employed. These preservatives are generally used at a concentration of about 0.00001 to 1 w / w%.

  Furthermore, antibacterial agents include sulfamethoxazole, sulfamethoxazole sodium, sulfisoxazole, sulfisomidine sodium and other sulfa drugs, ofloxacin, norfloxacin, levofloxacin, gatifloxacin, moxifloxacin New quinolone antibacterial agents such as syn, tosufloxacin, lomefloxacin, ciprofloxacin, aminoglycoside antibacterial agents such as tobramycin, gentamicin, micronomycin, dibekacin, sisomycin, tetracycline antibacterial agents such as tetracycline and minocycline, macrolides such as erythromycin And chloramphenicol antibacterial agents such as chloramphenicol, and cephem antibacterial agents such as cefmenoxime.

Furthermore, as vitamins, vitamin A (including retinol palmitate, β-carotene, etc.), vitamin B ₂ (flavin adenine nucleotide etc.), vitamin B ₆ (pyridoxine hydrochloride etc.), vitamin B ₁₂ (cyanocobalamin) Etc.), vitamin C (ascorbic acid etc.), vitamin Es (acetic acid-d-α-tocopherol etc.), panthenol and the like.

  In addition, examples of the focus control function improving agent include neostigmine methyl sulfate.

  Furthermore, examples of the intraocular pressure-lowering agent include betaxolol, timolol, dipivefrin, carteolol, latanoprost, tafluprost, travoprost, nipradilol, levobunolol and the like.

  Further, as the surfactant, any of conventionally known anionic surfactants, nonionic surfactants, amphoteric surfactants and cationic surfactants can be appropriately employed. Examples of the surfactant include polyglycerin fatty acid ester, polyoxyethylene-polyoxypropylene ethylenediamine, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene alkylphenyl ether formaldehyde condensate, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl Phenyl ether, polyoxyethylene glycerin fatty acid ester, polyoxyethylene sorbite fatty acid ester, polyoxyethylene castor oil, polyoxyethylene sterol, polyoxyethylene hydrogenated sterol, polyoxy Ethylene fatty acid ester, polyoxyethylene-polyoxypropylene alkyl ether, polyoxyethylene lanolin alcohol, polyoxyethylene alkylamine, polyoxyethylene alkylamide, polyoxyethylene alkyl ether phosphoric acid, polyoxyethylene-polyoxypropylene block polymer, Polysorbate, polyoxyethylene alkyl ether carboxylate, polyoxyethylene alkyl ether sulfate, alkyl fatty acid salt, alkyl phosphate, N-acyl taurine salt, alkyl glutamate, alkyl glycine salt, alkyl alanine salt, cocoyl fatty acid arginine, Alkyl sulfate, alkyl sulfonate, betaine acetate type amphoteric surfactant, alkyloxyhydroxypropyl arginine salt, imidazo Emission type amphoteric surfactants, quaternary alkylammonium salts, cocoylarginine ethyl PCA and the like. Such a surfactant is usually contained in the contact lens solution at a concentration of about 0.001 to 5 w / w%, preferably about 0.005 to 2 w / w%.

  Further, in addition to such drug components, in the contact lens solution according to the present invention, as in the conventional contact lens solution, a thickener, a chelating agent, a tonicity adjusting agent, a buffering agent, a corneal epithelium. Pharmaceutical components such as a disorder treatment agent, a solubilizing agent, fats and oils, and amino acids may be contained.

  In this context, the above thickener is contained in order to adjust the viscosity of the liquid agent for contact lenses. For example, polysaccharides such as alginic acid, chitosan and salts thereof, hyaluronic acid (salt), chondroitin Various gums such as mucopolysaccharides such as sulfuric acid (salt), heteropolysaccharides, polyvinyl alcohol (fully saponified and partially saponified), poly (meth) acrylic acid, poly-N-vinylpyrrolidone, poly Synthetic organic polymer compounds such as acrylamide, copolymer 845 (copolymer of polyvinylpyrrolidone and dimethylaminoethyl methacrylate), hydroxyethyl cellulose, hydroxypropyl methylcellulose 2208, hydroxypropyl methylcellulose 2906, hydroxypropylmethylcellulose 2910, carboxymethylcellulose, methyl Cellulose derivatives and starch derivatives such as loin is, at a concentration of about 0.001~10w / w%, is used.

  The chelating agent is a component for preventing deposition or adsorption of calcium or the like in tears on contact lenses, particularly soft contact lenses, and includes, for example, ethylenediaminetetraacetic acid (EDTA) and salts thereof, such as Ethylenediaminetetraacetic acid / disodium (EDTA · 2Na), ethylenediaminetetraacetic acid · trisodium (EDTA · 3Na) and the like are generally used at a concentration of about 0.001 to 0.5 w / w%.

  Furthermore, the tonicity adjusting agent (osmotic pressure adjusting agent) adjusts the osmotic pressure of the liquid for contact lenses to a value close to the osmotic pressure of tears to prevent eye irritation, contact lens standard changes, eye damage, etc. In order to avoid inducing, generally, inorganic salts such as sodium chloride and potassium chloride, sugars such as glucose, dextran, trehalose and derivatives thereof, sugar alcohols such as xylitol, erythritol, and At least one or more compounds selected from the group consisting of polyhydric alcohols such as propylene glycol and glycerin or ethers or esters thereof are usually in an osmotic pressure ratio with respect to physiological saline (where the osmotic pressure of physiological saline is 1). ), In an amount in the range of about 0.5 to 2.0, preferably in the range of about 0.6 to 1.6. Stomach, is allowed to contain.

  In addition, the aforementioned buffering agent may cause eye irritation or eye damage by adjusting the pH value of the liquid for contact lenses to about 3.5 to 9.0, particularly biologically safe pH. For example, carboxylic acids such as phosphoric acid, boric acid, citric acid and acetic acid, acids such as oxycarboxylic acid, and salts thereof (for example, sodium salts) Furthermore, Good-Buffer, Tris (hydroxymethyl) aminomethane (TRIS), bis (2-hydroxyethyl) iminotris (hydroxymethyl) methane (Bis-Tris), sodium hydrogen carbonate, aminoethylsulfonic acid, glycine, arginine, Amino acids such as glutamic acid are contained at a concentration that gives a pH value within the above-described range.

  The therapeutic agent for corneal epithelial disorder is a drug component for treating corneal epithelial disorder caused by dry eye, trauma, drug, etc., and examples thereof include hyaluronic acid and its salt, chondroitin sulfate and its salt, etc. Is generally used at a concentration of about 0.001 to 1 w / w%.

  Further, the solubilizing agent is a drug component for improving the solubility of a hardly soluble substance such as a water-insoluble drug, and for example, a lower or higher alcohol such as ethanol, isopropanol, oleyl alcohol, lauryl alcohol, etc. Can be mentioned.

  In addition, fats and oils are components blended for the purpose of reducing friction on the ocular surface and supplementing the tear oil layer. For example, almond oil, lanolin, olive oil, oleic acid and / or its salt, limonene, liquid paraffin , Triglyceride, squalane, petrolatum, silicone oil, sesame oil, perilla oil, soybean oil, camellia oil, corn oil, jojoba oil, castor oil, and generally, at a concentration of about 0.0001 to 3 w / w% Used.

Examples of amino acids used in the present invention include aspartic acid and salts thereof, tranexamic acid, L-cysteine, alanine, lysine, anserine, carnosine and the like, and vitamins include vitamin A (palmitic acid). Including retinol and β-carotene), vitamin B ₂ (such as flavin adenine nucleotide sodium), B ₆ (such as pyridoxine hydrochloride), B ₁₂ (such as cyanocobalamin), vitamin C (ascorbic acid), d-α-tocopherol acetate, etc. Vitamin E, panthenol and the like. Furthermore, the sulfa drug is a component mainly used as an antibacterial agent, and examples thereof include sulfamethoxazole, sulfamethoxazole sodium, sulfisoxazole, and sulfisomidine sodium. The As antibacterial agents, in addition to the sulfa drugs described above, antibacterial agents such as ofloxacin and new quinolone antibacterial agents can also be used.

  Furthermore, in the contact lens solution according to the present invention, in addition to the above-described components, if necessary, one kind of various pharmaceutical components conventionally used in contact lens solutions. Even if two or more kinds are contained, there is no problem. In addition, it is preferable that such a drug component is highly safe to the living body, is ophthalmically acceptable, and does not adversely affect the shape and physical properties of the contact lens. It is desirable to be used within a quantitative range that satisfies the above.

  In addition, in the present invention, the above-described pharmaceutical components are contained in a liquid medium alone or in combination of two or more. In such a liquid medium, It is not necessary that all drug components to be contained can be included in the compound A having a cyclic or cylindrical molecular structure described later, and at least one of these drug components is a compound described later. If it is included in A, the above-described effects of the present invention can be fully enjoyed. Therefore, in the contact lens solution according to the present invention, it is included in the compound A. There can be no adverse drug component present in the liquid medium.

  In the contact lens solution according to the present invention, a compound having a cyclic or cylindrical molecular structure (compound A) is contained in the liquid medium together with the drug components as described above. However, in the present invention, such a compound A is ophthalmically acceptable, and is particularly capable of inclusion of at least one drug component and compound B having a chain molecular structure described later. It is not limited, and any of various compounds having a cyclic or cylindrical molecular structure can be employed. As such compound B, for example, cyclodextrins having a structure in which a number of D-glucopyranose groups are cyclized in a crown shape by α1 → 4 glycosidic bonds, and crown ethers that are cyclic polyethers, Examples thereof include carbon nanotubes that are tubular (tubular) carbon molecules, and calixarenes that are cyclic compounds obtained by reacting formaldehyde with a phenol derivative.

  In particular, in the present invention, among the compounds A as described above, the safety to the living body is high, and a moisturizing effect and a thickening effect can be imparted to the liquid agent for contact lenses. Cyclodextrins are preferably used because the following excellent effects can be advantageously achieved by enclosing various drug components.

  That is, when such a cyclodextrin is contained in a liquid medium together with the drug component, the drug component is included in the pores of the cyclodextrin, thereby causing undesirable adsorption and action of the drug component. This is advantageously suppressed. Specifically, when a drug component is included in the pores of cyclodextrins, the adsorption or action of the drug component on contact lenses, formulation containers, biological tissues, etc. is advantageously suppressed. .

  Such cyclodextrins are not particularly limited in the present invention. For example, glucose polymerization such as α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, and δ-cyclodextrin Degree: cyclodextrin of about 6-9 can be used, and in addition, methylated cyclodextrin, hydroxyethylated cyclodextrin, maltosyl-α-cyclodextrin, hydroxyethyl-β-cyclodextrin, triacetyl-β -Cyclodextrin derivatives such as cyclodextrin and hydroxypropylated cyclodextrin, and cyclodextrin multimers such as cyclodextrin dimer are appropriately used. Among these, α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin are preferably used because the inclusion compound with the polyoxyethylene derivative described later is less toxic.

  In addition, the content of the compound A having a cyclic or cylindrical molecular structure as described above in the contact lens solution is not particularly limited in the present invention. Is preferably used at a concentration such that it can be advantageously controlled, generally at a concentration of about 0.001 to 20.0 w / w%, more preferably at a concentration of about 0.005 to 5.0 w / w%. Will be used. When the content of Compound A is too large, the osmotic pressure increases, which may cause problems of solubility and eye irritation. When the content of Compound A is too small, the above-mentioned book There is a possibility that the effects of the invention cannot be fully enjoyed.

  In the present invention, in the liquid medium containing the drug component and the compound A as described above, the compound B which has a chain molecular structure and can be included in the compound A It is contained.

  As described above, the contact lens solution according to the present invention further has a chain molecular structure in the liquid medium containing the compound A having a cyclic or cylindrical molecular structure together with the drug component. In addition, since the compound B that can be included in the compound A is contained, in the pores of the compound (compound A) having a cyclic or cylindrical molecular structure such as cyclodextrin, Competitively or in exchange with various drug components, Compound B having a chain molecular structure comes to be included, and thereby, the drug action of each drug component is respectively It can be used advantageously.

  That is, in the conventional liquid medicine for contact lenses, when compound A having a cyclic or cylindrical molecular structure is contained in a liquid medium together with various drug components, various liquid substances contained in the liquid medium are included. The drug component can be encapsulated in the ring or cylinder (in the vacancies) of the compound A having a cyclic or cylindrical molecular structure. In the case of the drug component encapsulated, the drug effect inherent to the drug component cannot be sufficiently exhibited. On the other hand, in the liquid preparation for contact lenses according to the present invention, in addition to the drug component and the compound having a cyclic or cylindrical molecular structure (compound A) in the liquid medium, a chain molecular structure is further provided. And the compound (compound B) that can be included in the compound A is contained in the pores of the compound A, the compound B is competitively or exchanged with the drug component. Thus, inclusion of the drug component to compound A is advantageously controlled, so that the drug action of such drug component is advantageously and effectively controlled. Therefore, the drug effect can be exerted advantageously. That is, in the contact lens solution according to the present invention, the drug action of a drug component such as a preservative can be reduced even in the presence of a cyclic or cylindrical molecular structure (compound A) such as cyclodextrin. This can be advantageously prevented.

  In addition, in the contact lens solution according to the present invention, by adding and containing Compound B, the pores of Compound A having a cyclic or cylindrical molecular structure are competitive with the above-described drug components. Alternatively, since the compound B comes to be included in an exchange, the drug component is pushed out from the pores of the compound A. Even in this case, as described above Further, an advantageous effect realized by including a compound having a cyclic or cylindrical molecular structure (compound A) such as cyclodextrin together with a drug component, for example, adsorption of a bactericide to a contact lens, a container or the like Inhibitory effect, solubility improvement effect of poorly soluble substances such as water-insoluble drugs, bitterness reducing effect such as antihistamines and anti-inflammatory agents, stimulant mitigation effects such as cooling agents, bactericides and preservatives such as PHMB Drug corneal staining suppress or prophylactic effect, such as by What like, without being loss, their effects, which may occur as it can be advantageously enjoyed.

  In the contact lens solution according to the present invention, the compound B is not particularly limited as long as it has a chain molecular structure and can be included in the compound A. Either a chain or a branched chain may be used, and various known compounds that are ophthalmically acceptable and have compatibility with contact lenses can be used as appropriate. However, in the present invention, water-soluble polymers such as polyalkylene glycol such as polyethylene glycol (PEG), polyoxyethylene alkyl ether, Polyoxyal such as polyoxyethylene alkyl ester, polyoxyethylene-polyoxypropylene block copolymer Ren derivatives advantageously used, among which, in the present invention, from where excellent inclusion against the aforementioned cyclodextrin, polyethylene glycol, more preferably used.

  Further, the molecular weight of such compound B is not particularly limited, but the inclusion compound with the above-mentioned cyclodextrins (compound A) can be formed advantageously and stably in a pharmaceutical manner. The weight average molecular weight is preferably 500 or more, and more preferably about 2000 to 40,000. In addition, when the weight average molecular weight of the compound B is too small, the inclusion compound of the compound B and the compound A may not be stably formed, and the treated contact lens is swollen thereby. The standard of the contact lens may be changed. On the other hand, when the weight average molecular weight of the compound B is too large, the solubility of the compound B in the liquid medium may be deteriorated.

  Further, the content of such compound B in the liquid preparation for contact lens is not particularly limited in the present invention, but the drug action of the drug component can be advantageously exerted. It is desirable to be used at a concentration, and it is usually used at a concentration of about 0.001 to 10.0 w / w%, preferably at a concentration of about 0.005 to 5.0 w / w%. In addition, when there is too much content of such a compound B, while there is a possibility that osmotic pressure may increase and irritation to eyes may become strong, the drug action of a drug ingredient can be controlled effectively. May be difficult. On the other hand, when the content of the compound B is too small, the effects as described above due to the addition and inclusion of the compound B may not be sufficiently enjoyed.

  In addition, the ratio of the content of the compound A and the compound B in the contact lens solution according to the present invention is not particularly limited, but the drug action of the drug component coexisting in the solution is advantageously controlled. In order to make it squeeze, it is generally contained in a weight ratio of about 1000: 1 to 1: 1000, preferably about 500: 1 to 1: 500.

As described above, the contact lens solution according to the present invention comprises compound A and compound B as described above together with various drug components in a liquid medium. When cyclodextrins as described above are used, and when a polyoxyethylene derivative such as polyethylene glycol is used as the compound B, the inclusion compound formed by the compound A and the compound B is a pseudorotaxane. A (pseudorotaxane) structure or a pseudopolyrotaxane (pseudopolyrotaxane) structure will be exhibited. In such an inclusion compound having a pseudorotaxane structure or a pseudopolyrotaxane structure, the formation or release of the inclusion compound is easy, so that the drug action of the drug component can be controlled more advantageously. Therefore, in the present invention, a combination of Compound A and Compound B that forms such an inclusion compound having a pseudorotaxane structure or a pseudopolyrotaxane structure is preferably employed. is there. More specifically, such a combination of Compound A and Compound B includes, for example, α-cyclodextrin as Compound A and Macrogol 600, Macrogol 1000, Macrogol 1500, Macrogol 1540, Macro as Compound B A combination with at least one selected from the goal 4000 and the macro goal 6000 is exemplified.

  Further, in the absence of the above-described drug component, the inclusion compound is formed by the compound A and the compound B, whereby the toxicity of the compound B can be effectively reduced. In this respect, the characteristics of the present invention can be found.

  In producing the contact lens solution according to the present invention as described above, the above-described components, that is, the predetermined drug component, Compound A and Compound B, are respectively contained in an appropriate liquid medium in the same manner as in the prior art. In addition to water itself, such as tap water, purified water, distilled water, etc., the liquid medium used at that time will be carried out by adding it in an appropriate amount and dissolving and containing it. Any water-based solution can be used as long as it is highly safe to the living body and is sufficiently ophthalmically acceptable. In addition, in preparing such a contact lens solution, no special method is required, and each component can be added to the liquid medium in any order as in the case of preparing a normal aqueous solution. It can be easily obtained by dissolving. Furthermore, the container to be filled is not limited at all, and a single layer or a multilayer structure of polyethylene terephthalate, polyethylene, polypropylene, polycarbonate or the like is appropriately selected.

  The use form of the contact lens solution according to the present invention obtained as described above is not limited in any way. For example, the contact lens cleaning solution, the rinsing solution, the mounting solution, the storage solution, the protein removing agent or the As a multi-purpose solution, etc., as a contact lens packaging solution, an eyewash solution or an eye drop solution that can be used while wearing a contact lens, and a multi-purpose preparation that combines these functions (eg, eye drop solution, (Eye drops) can be prepared and used as appropriate.

  Further, when the contact lens solution according to the present invention is used, the types of contact lenses (including fashion color contact lenses) are not limited in any way, and soft contact lenses (ionic) And non-ionic), hard contact lenses (including oxygen-permeable hard contact lenses), and hybrid contact lenses combining soft contact lenses and hard contact lenses. It may be a contact lens made of silicone hydrogel. Further, such contact lenses can be non-hydrous, low hydrous, and high hydrous, regardless of whether or not they are surface-treated. In addition, disposable contact lenses typified by daily disposable contact lenses, regular exchange contact lenses, frequent exchange contact lenses, and conventional contact lenses that are used until the end of their lives are covered. Such a contact lens may be an all day wear type or a continuous wear type.

  Hereinafter, some examples of the present invention will be shown and the present invention will be more specifically clarified, but the present invention is not limited by the description of such examples. It goes without saying. In addition to the following examples, the present invention can be subjected to various changes, corrections, improvements and the like based on the knowledge of those skilled in the art without departing from the spirit of the present invention. Should be understood.

-Test solution 1-
First, benzalkonium chloride (manufactured by Nacalai Tesque Co., Ltd.) is used as a drug component, α-cyclodextrin (manufactured by Wako Pure Chemical Industries, Ltd.) is used as compound A, and weight average is used as compound B. While using polyethylene glycol having a molecular weight of 6000 (Macrogol 6000, manufactured by NOF Corporation) and using sodium hydrogen phosphate and sodium dihydrogen phosphate as buffering agents, they are blended as shown in Table 1 below. Then, a solution for contact lens (sample solution 1) was prepared by dissolving each in purified water.

  Next, the antiseptic effect of the prepared contact lens solution was evaluated as follows. And the obtained result is combined with following Table 1, and is shown.

[Preservation effect]
The test was carried out with reference to “15th Amendment Japanese Pharmacopoeia Reference Information 28. Preservative Efficacy Test”. Specifically, Pseudomonas aeruginosa was inoculated into the contact lens solution prepared above so that it would be 10 ⁵ to 10 ⁶ per mL, and cultured at 22 ° C. for 14 days. I did it. And the viable cell count after culture | cultivation was measured, the survival rate of a microbe was computed from the viable cell count after culture | cultivation with respect to the inoculum count, and it evaluated based on the following references | standards. In addition, using Escherichia coli and Staphylococcus aureus as test bacteria, a storage efficacy test was performed in the same manner as described above, and the survival rate of the bacteria was calculated, based on the following criteria: And evaluated.
A: No bacteria were detected.
(Triangle | delta): The survival rate of a microbe was 0.1% or more.
X: Bacteria were growing.

-Test solution 2-
Except for using 0.000025 w / v% of polyhexamethylene biguanide (polyhexanide hydrochloride, manufactured by Arch Chemicals Japan Co., Ltd.) instead of 0.01 w / v% of benzalkonium chloride as the drug component, A contact lens solution was prepared in the same manner as in Test solution 1. The prepared contact lens solution was evaluated for antiseptic effects in the same manner as described above. The obtained results are also shown in Table 1 below.

-Test solution 3-
A contact lens solution was prepared in the same manner as in Test solution 1, except that the blending ratio of polyethylene glycol was changed to 0.25 w / v% instead of 1.5 w / v%. The prepared contact lens solution was evaluated for antiseptic effects in the same manner as described above. The obtained results are also shown in Table 1 below.

-Test solution 4-
A contact lens solution was prepared in the same manner as in the test solution 1, except that 0.83 w / v% of sodium chloride was used as the tonicity adjusting agent. The prepared contact lens solution was evaluated for antiseptic effects in the same manner as described above. The obtained results are also shown in Table 1 below.

-Comparative solution 1 and Comparative solution 2-
A comparative solution 1 was prepared in the same manner as the sample solution 1 except that polyethylene glycol was not used at the blending ratio shown in Table 2 below. Further, Comparative Solution 2 was prepared in the same manner as in Test Solution 2, except that polyethylene glycol was not used, at the blending ratio shown in Table 2 below. And about the comparison liquid 1 and the comparison liquid 2, it evaluated the antiseptic effect similarly to the above. The obtained results are also shown in Table 2 below.

-Comparative solution 3 and Comparative solution 4-
Comparative solution 3 was prepared in the same manner as test solution 1, except that α-cyclodextrin was not used. Further, Comparative Solution 4 was prepared in the same manner as Test Solution 1 except that α-cyclodextrin and polyethylene glycol were not used. And about the comparison liquid 3 and the comparison liquid 4, it carried out similarly to the above, and evaluated the antiseptic effect, respectively. The obtained results are shown together with the blending ratio in Table 2 below.

-Comparative solution 5 and Comparative solution 6
Comparative solution 5 was prepared in the same manner as test solution 2, except that α-cyclodextrin was not used. Further, Comparative Solution 6 was prepared in the same manner as Test Solution 2, except that α-cyclodextrin and polyethylene glycol were not used. And about the comparative liquid 5 and the comparative liquid 6, it carried out similarly to the above and evaluated the antiseptic effect. The obtained results are shown together with the blending ratio in Table 2 below.

  As is clear from the results of Tables 1 and 2, in the contact lens solution (test solutions 1 to 4) according to the present invention, the comparative solution 3 and comparative solution 5 containing no α-cyclodextrin, α -It was recognized that it had the same preservative effect as the comparative liquid 4 and the comparative liquid 6 which do not contain cyclodextrin and polyethylene glycol. On the other hand, the conventional contact lens solution (Comparative Solution 1 and Comparative Solution 2) containing α-cyclodextrin and not containing polyethylene glycol which can be included in the α-cyclodextrin has a sufficient antiseptic effect. It was recognized that it was not. This is because α-cyclodextrin (compound A) in which benzalkonium chloride and polyhexamethylene biguanide having antiseptic and disinfecting effects coexist in the liquid for contact lens in the liquid for contact lens of Comparative liquid 1 and Comparative liquid 2. ), The drug action could not be sufficiently exerted, whereas in the contact lens solution according to the present invention, such benzalkonium chloride or polyhexamethylene The inclusion of biguanide into α-cyclodextrin (compound A) is considered to be the result of effective control by polyethylene glycol (compound B) coexisting in the liquid for contact lenses.

-Comparative solution 7-
As a pharmaceutical ingredient, 0.01 w / v% of benzalkonium chloride is used, 0.1 w / v% of α-cyclodextrin is used as compound A, and 0.6 w / v of sodium hydrogen phosphate is used as a buffer. Comparative solution 7 was prepared using v% and 0.08 w / v% of sodium dihydrogen phosphate.

  Then, the test solutions 1 and 3 and the comparative solution 7 which are contact lens solutions prepared as described above were evaluated for cytotoxicity as follows, respectively, and in the same manner as described above, the antiseptic effect ( Evaluation of test bacteria: Pseudomonas aeruginosa). The results are also shown in Table 3 below together with the blending ratio.

[Cytotoxicity]
First, a fresh medium (MEM solution supplemented with 5 vol% fetal calf serum) was injected into a multiplate for cell culture, and about 50 V79 cells (Chinese hamster lung-derived fibroblasts) were seeded there. Then, the multiplate was accommodated in a carbon dioxide culture apparatus maintained at 37 ° C., and cultured for about 24 hours at a carbon dioxide concentration of 5%. Thereafter, the culture solution in the well was removed, and the test solution 1, 3 and the comparison solution 7 that were prepared in the above were diluted 100 times with 5 vol% fetal calf serum-added MEM solution into the well. The aliquot was dispensed and kept in a carbon dioxide culture apparatus for 6-7 days. After such incubation, the contact lens solution is removed from each well, the cells are fixed by adding ethanol for about 5 minutes, and then adding about 2 vol% Giemsa solution for about 30 minutes. Cells were stained. Then, the stained cells were observed with a stereomicroscope, and the number of colonies was counted with a colony in which 50 or more cells gathered as one colony.

  On the other hand, as a blank, a fresh medium (5 vol% fetal calf serum-added MEM solution) was injected into a cell culture multiplate, and about 50 V79 cells (Chinese hamster lung-derived fibroblasts) were seeded there. Thereafter, the cells were cultured in a carbon dioxide culture apparatus maintained at 37 ° C. for 1 week, and the number of colonies was measured by staining the medium after the culture.

Subsequently, the colony formation rate was calculated from the measured number of colonies formed in the contact lens solution and in the blank (fresh medium) according to the following formula 1, respectively.
Colony formation rate (%)
= [(Average number of colonies formed in the liquid for contact lenses)
/ (Average number of colonies formed with blanks)] × 100 (%) (Formula 1)

Based on the colony formation rate obtained above, cytotoxicity was evaluated based on the following criteria.
A: The colony formation rate was 50% or more.
(Circle): The colony formation rate was 40% or more and less than 50%.
X: The colony formation rate was less than 40%.

  As is apparent from the results in Table 3, since the test solution 1 and the test solution 3 according to the present invention contain polyethylene glycol together with α-cyclodextrin, its cytotoxicity is low, and the eye It has been confirmed that the drug action (preservative effect) of the drug component (benzalkonium chloride) can be effectively exhibited. On the other hand, in the comparative solution 7 in which the deterioration of the antiseptic effect due to the addition of α-cyclodextrin was supplemented with EDTA or boric acid, although the antiseptic effect was sufficiently obtained, the colony formation rate was low and the toxicity was strong. It was recognized that there was.

-Comparison solution 8-
A contact lens solution was prepared in the same manner as the test solution 4 except that polyethylene glycol was not used. The prepared contact lens solution was subjected to the following benzalkonium chloride adsorption test. The results are shown together with the blending ratio in Table 4 below.

[Benzalkonium chloride adsorption test]
First, 2 mL of the contact lens solution prepared above was weighed into a glass vial, and one soft contact lens (1.DAY ACUVUE, manufactured by Johnson & Johnson Co., Ltd.) was immersed therein. Next, the glass vial in which the contact lens was immersed was shaken at room temperature for about 8 hours, and then the lens was taken out. And the light absorbency in 263 nm of the liquid agent for contact lenses before and behind immersion of a contact lens was measured, and the adsorption amount of benzalkonium chloride was computed according to the following formula 2.
Benzalkonium chloride adsorption (μg)
= [(Absorbance of liquid for contact lens-Absorbance of liquid for contact lens after immersion)
/ (Absorbance of liquid for contact lens)] × 200 (μg) (Formula 2)

-Comparison solution 9-
A contact lens solution was prepared in the same manner as in Test Solution 4, except that α-cyclodextrin and polyethylene glycol were not used, and the amount of sodium chloride was 0.6 w / v%. The adjusted contact lens solution was subjected to a benzalkonium chloride adsorption test in the same manner as described above to calculate the amount of benzalkonium chloride adsorbed. The results are shown together with the blending ratio in Table 4 below.

  In addition, the benzalkonium chloride adsorption test was performed in the same manner for the test solution 4 prepared above, and the amount of benzalkonium chloride adsorbed was calculated. The results are also shown in Table 4 below.

  As is apparent from the results of Table 4, in the test solution 4 containing α-cyclodextrin and polyethylene glycol together with benzalkonium chloride, the adsorption of benzalkonium chloride to the contact lens was not achieved. It was found that the antiseptic effect of benzalkonium chloride was exerted advantageously while being effectively suppressed. On the other hand, in the comparative solution 8 containing no polyethylene glycol, although the adsorption of benzalkonium chloride to the contact lens is suppressed by α-cyclodextrin, the antiseptic effect of benzalkonium chloride cannot be sufficiently obtained. It was recognized that Moreover, in the comparative solution 9 which does not contain α-cyclodextrin and polyethylene glycol, the antiseptic effect of benzalkonium chloride is sufficiently exhibited because it does not contain α-cyclodextrin. Adsorbed in large amounts on contact lenses and was found to be inferior in eye safety.

-Test solution 5-
Further, chlorpheniramine maleate is used as a drug component (antihistamine), α-cyclodextrin (manufactured by Wako Pure Chemical Industries, Ltd.) is used as compound A, and compound B has a weight average molecular weight of 6000. Using polyethylene glycol (Macrogol 6000, manufactured by NOF Corporation), a contact lens solution (Test Solution 5) was prepared at a blending ratio shown in Table 5 below. In addition, as a medium of the test solution 5, a HuMedia-EG2 culture solution (manufactured by Kurashiki Boseki Co., Ltd.) was used instead of purified water for the following antihistamine activity test. And the following antihistamine activity tests were done about this prepared contact lens solution. The results are shown in Table 5 below together with the blending ratio.

[Antihistamine activity test]
First, human umbilical cord-derived normal vascular endothelial cells (distributed from Human Science Research Resource Bank, resource number: IF050271, resource name: HUV-EC-C) are placed on a 24-well plate for tissue culture (manufactured by Becton Dickinson Japan). Seeding was performed at about 3000 pieces / cm ² . Then, using the HuMedia-EG2 culture solution, culturing for 6 days, removing the culture solution, adding the contact lens solution (sample solution 5) prepared above, and culturing for 1 hour, Further, after removing the culture solution, the culture was carried out for 20 hours using a HuMedia-EG2 culture solution containing 0.00111 w / v% histamine. The culture was performed under the conditions of temperature: 37 ° C. and CO ₂ concentration: 5%. After completion of the culture, the concentration of interleukin-8 (IL-8) in the culture solution was measured by oxygen-linked immunosorbent assay (ELISA).

-Comparative solution 10 and Comparative solution 11-
A comparative solution 10 was prepared in the same manner as the test solution 5 except that polyethylene glycol was not used. In addition, Comparative Solution 11 was prepared in the same manner as Test Solution 5 except that α-cyclodextrin was not used. And about the prepared comparison liquid 10 and the comparison liquid 11, it carried out similarly to the above, and performed the antihistamine activity test. The results are also shown in Table 5 below.

-Comparative solution 12 and Comparative solution 13-
Comparative solution 12 was prepared by containing 0.00039 w / v% chlorpheniramine maleate in the HuMedia-EG2 culture solution. In addition, as a comparison solution 13, a HuMedia-EG2 culture solution was prepared. And about the comparative liquid 12 and the comparative liquid 13, the antihistamine activity test was done like the above. The results are also shown in Table 5 below.

-Comparison solution 14-
About 3,000 human umbilical cord-derived normal vascular endothelial cells (distributed from Human Science Research Resource Bank, resource number: IF050271, resource name: HUV-EC-C) in a 24-well plate for tissue culture (manufactured by Becton Dickinson, Japan) Seeds / cm ² . Then, after culturing for 6 days using the HuMedia-EG2 culture solution and removing the culture solution, the HuMedia-EG2 culture solution was added as the comparison solution 14 and further cultured for 21 hours. The culture was performed under the conditions of temperature: 37 ° C. and CO ₂ concentration: 5%. After completion of the culture, the concentration of interleukin-8 (IL-8) in the culture solution was measured by oxygen-linked immunosorbent assay (ELISA). The results are also shown in Table 5 below.

  As is apparent from the results in Table 5, in Comparative Solution 13, the production of interleukin-8 in the cells was enhanced by the addition of histamine, and the concentration of interleukin-8 in the culture solution was increased. . Moreover, in the comparison liquid 12 containing chlorpheniramine maleate, which is an antihistamine, chlorpheniramine maleate antagonized histamine and suppressed the production of interleukin-8, so the interleukin-8 concentration was lowered. It was. Further, in the comparative solution 11 containing polyethylene glycol in addition to chlorpheniramine maleate, the concentration of interleukin-8 was lowered as in the comparative solution 12. In the comparative solution 10 which is a conventional contact lens solution containing α-cyclodextrin together with chlorpheniramine maleate, the interleukin is compared with the comparative solution 12 which does not contain α-cyclodextrin. -8 concentration became high. This is presumably because chlorpheniramine maleate was included in the pores of α-cyclodextrin and the antihistaminic activity was suppressed. On the other hand, in the test solution 5 containing polyethylene glycol together with chlorpheniramine maleate and α-cyclodextrin, the interleukin-8 concentration was low. This is because inclusion of chlorpheniramine maleate (drug component) in α-cyclodextrin (compound A) is effectively controlled by polyethylene glycol (compound B), and the antihistamine activity of chlorpheniramine maleate is It is thought that this is a result that has been demonstrated to an advantage.

-Test solution 6
Instead of 0.01 w / v% of benzalkonium chloride, 0.03 w / v% of chlorpheniramine maleate was used, and the blending ratio of polyethylene glycol was changed to 1.5 w / v%. A contact lens solution (Test Solution 6) was prepared in the same manner as Test Solution 4, except that the concentration was 5 w / v%. The prepared contact lens solution was subjected to the following chlorpheniramine maleate adsorption test. The results are shown together with the blending ratio in Table 6 below.

[Chlorpheniramine maleate adsorption test]
First, 2 mL of the contact lens solution prepared above was weighed into a glass vial, and one soft contact lens (1.DAY ACUVUE, manufactured by Johnson & Johnson Co., Ltd.) was immersed therein. Next, the glass vial in which the contact lens was immersed was shaken at room temperature for about 8 hours, and then the lens was taken out. Then, the absorbance at 261 nm of the contact lens solution before and after immersion of the contact lens was measured, and the adsorption amount of chlorpheniramine maleate was calculated according to the following formula 3.
Chlorpheniramine maleate adsorption (μg)
= [(Absorbance of liquid for contact lens-Absorbance of liquid for contact lens after immersion)
/ (Absorbance of liquid for contact lens)] × 600 (μg) (Formula 3)

-Comparative solution 15 and Comparative solution 16-
A comparative solution 15 was prepared in the same manner as the test solution 6 except that polyethylene glycol was not used. Moreover, the comparison liquid 16 was prepared like the test liquid 6 except having decided not to use (alpha) -cyclodextrin and polyethyleneglycol. And about the adjusted comparative liquid 15 and the comparative liquid 16, it carried out similarly to the above, the maleic acid chlorpheniramine adsorption test was done, and the maleic acid chlorpheniramine adsorption amount was computed. The results are also shown in Table 6 below.

  As is apparent from the results in Table 6, it was confirmed that the adsorption of chlorpheniramine maleate to the contact lens was suppressed in the comparative solution 15 containing α-cyclodextrin, and α- In Comparative Solution 16 containing no cyclodextrin, it was observed that chlorpheniramine maleate was adsorbed in large amounts on the contact lens. On the other hand, even in the test liquid 6 containing polyethylene glycol (compound B) together with α-cyclodextrin (compound A), the adsorption of chlorpheniramine maleate to the contact lens contains α-cyclodextrin, It was suppressed to the same extent as that of Comparative Solution 15 containing no polyethylene glycol, and it was confirmed that the adsorption suppressing effect of α-cyclodextrin on chlorpheniramine maleate can be sufficiently exhibited even in the presence of polyethylene glycol.

[Poloxamer toxicity reduction test]
In the blending ratio shown in Table 7 below, α-, β- or γ-CD (cyclodextrin) as compound A and poloxamer as compound B (polyoxyethylene polyoxypropylene glycol; Lutorol, manufactured by BASF) Sample solutions 7, 8, and 9 were prepared by dissolving in purified water. For comparison, a comparative solution 17 was prepared by dissolving only the poloxamer in purified water.

  And the above-mentioned cytotoxicity test was implemented about those obtained test liquids 7-9 and the comparison liquid 17, and the result was combined with following Table 7 as colony formation rate.

  As apparent from the results of Table 7, the colony formation rate is high in the test solutions 7 to 9 by allowing cyclodextrin (CD) to coexist with the poloxamer as compared with the case of poloxamer alone (Comparative solution 17). became. Therefore, it is considered that the cytotoxicity of the poloxamer has decreased due to the formation of the pseudorotaxane or pseudopolyrotaxane structure between the poloxamer and the cyclodextrin. Cyclodextrins include α, β, and γ types, each having a different ring size. It is inferred that the colony formation rates are different in the test solutions 7 to 9 because the formation rates of pseudo-rotaxane and pseudo-polyrotaxane of cyclodextrin and poloxamer are different.

[Polyethylene glycol toxicity reduction test]
In the blending ratios shown in Table 8 and Table 9 below, α-, β- or γ-CD (cyclodextrin) as Compound A and PEG 600 (Polyethylene glycol having a weight average molecular weight of 600; Macrogol 600; (Manufactured by NOF Corporation) or PEG6000 (polyethylene glycol having a weight average molecular weight of 6000; Macrogol 6000, manufactured by NOF Corporation) is dissolved in MEM solution containing 5 vol% fetal calf serum, and further filtered through a 0.22 μm filter. And sterilized to prepare test solutions 10-12 and 13-15. For comparison, only PEG 600 or PEG 6000 was dissolved in 5 vol% fetal calf serum-added MEM solution, further sterilized by filtration through a 0.22 μm filter, and comparative solutions 18 and 19 were prepared, respectively.

  And the above-mentioned cytotoxicity test was implemented about those obtained test liquids 10-12 and 13-15, and the comparison liquids 18 and 19, and the result was made into the following Table 8 and Table 9 as a colony formation rate. Also shown. The cytotoxicity test was performed using the test solution and the comparison solution as they were without diluting the test solutions 10 to 12, 13 to 15 and the comparison solutions 18 and 19 with the 5 vol% fetal calf serum-added MEM solution.

  As shown in Tables 8 and 9, as compared with the case of PEG alone (Comparative solutions 18 and 19), by allowing cyclodextrin to coexist with PEG, any of the test solutions 10 to 12 and 13 to 15 Also, the colony formation rate increased. Therefore, it is considered that PEG and cyclodextrin formed a pseudorotaxane or pseudopolyrotaxane structure, thereby reducing the cytotoxicity of PEG. The reason why the colony formation rates are different in the test solutions 10 to 12 and 13 to 15 is that, similarly to the poloxamer, the ring sizes of the respective cyclodextrins are different, and the formation rate of pseudo rotaxane or pseudo polyrotaxane with PEG is different. Inferred.

Both PEG600 and PEG6000 are considered to easily form α-cyclodextrin and a pseudorotaxane or pseudopolyrotaxane structure.

Claims (4)

The compound A contains at least one selected from the group consisting of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin, and the compound B has a polyethylene glycol having a weight average molecular weight of 2000 to 40000 as 0 It contains a concentration of .005~5.0w / w%, and the compound B with those compounds a, in a weight ratio of 1: 1 to 1: is the additional inclusion in the 15 ratio, further, antiallergic agents, anti-inflammatory Agent, vasoconstrictor, refreshing agent, antiseptic / bactericidal agent, focus control function improving agent, intraocular pressure-lowering agent, vitamins, antibacterial agent (antibiotic) and surfactant A drug component that can be included in the compound A is contained, and the drug component and the compound A are included in a molar ratio of 1: 3.64 to 1: 309. A contact lens solution characterized by the above. The weight ratio of the previous SL pharmaceutical ingredient and the compound B is 1: 16.67 to 1: 60000 a liquid formulation for contact lenses according to claim 1, characterized in that. It said compound B is, Ma Kurogoru 4000, macrogol 6000, liquid formulation for contact lenses according to claim 1 or claim 2, characterized in that at least one selected from the group consisting of macrogol 20000. A chain comprising a predetermined drug component and at least one compound A having a cyclic or cylindrical molecular structure selected from the group consisting of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin; A compound B composed of polyethylene glycol having a molecular weight structure and being included in the compound A and having a weight average molecular weight of 2,000 to 40,000 at a concentration of 0.005 to 5.0 w / w%, and In a liquid preparation in which the compound A and the compound B are contained in a weight ratio of 1: 1 to 1:15, the compound B is included in the compound A, and a pseudo rotaxane structure or Controls the drug action of the drug component that can be included in the compound A by forming a pseudopolyrotaxane structure. Method.